10/05/2026
BREAKING NEWS: Germfree Launches Biopharmaceutical Isolator for Advanced Therapy Workflows 👀👇
Ormond Beach, FL, October 5, 2026 — Germfree, a full-lifecycle engineering and manufacturing partner for mission-critical environments across life sciences, healthcare and biocontainment, today launched a new aseptic biopharmaceutical isolator designed to provide a flexible, modular Grade A processing environment for cell and gene therapy (CGT) applications. The new technology, made and serviced in the U.S., will enable CGT developers to bolster their contamination control strategy around open steps in manufacturing workflows.
Germfree is bringing the new aseptic isolator to market in response to rising customer demand, especially for their critical role in the manufacture of CGTs. The introduction of the new platform aligns with Germfree’s mission to create environments that serve the CGT industry. Until now, the company has been building bespoke aseptic isolators on request as a service for customers seeking a superior alternative to off-the-shelf options, oftentimes made from less-robust materials leading to quality and longevity concerns.
The aseptic isolator’s fully welded, complete 316 stainless-steel construction is designed to support frequent cleaning and decontamination. Configurable shelving, racks, and pe*******on locations allow the system to be adapted to individual workflows while preserving the cost efficiency and lead times of a standardized platform. Additionally, it is manufactured in the U.S. and serviced with a US-based team, helping to secure supply chains that underpin rapid CGT scalability.
🔗 Read the full story. ➡️ https://hubs.ly/Q04z7z-50
